OBJECTIVE: To evaluate the results of first-trimester combined screening for @entity1467 in @entity1 with @entity740 . METHOD: Fifty-five pregnant @entity1 with @entity8 were compared with 110 @entity1 matched for maternal age, maternal weight, smoking status, and gestational age. @entity177 was assayed at the time of the combined screening and @entity177 was defined by serum @entity1011 >90     mol/L and renal clearance <80   mL/min. We defined 3 groups: @entity8 and normal renal function (group 1), @entity8 and @entity177 (group 2), and a control group (group 3). The values of nuchal translucency, @entity15714 , @entity1465 and false-positive rates for @entity1467 screening were compared. RESULTS: There were 39 (71%) and 16 (29%) cases in groups 1 and 2, respectively. Nuchal translucency and MoM @entity15714 were similar in the three groups. However, MoM @entity1465 levels were higher in group 2 than in groups 1 and 3 (5.37 vs 1.1 vs 0.98 MoM, p   =   0.0001). The resulting screen-positive rate was also higher in group 2 than in groups 1 and 3 (43.7% vs10.2% vs 5.5%, p =0.0001). CONCLUSION: Trisomy 21 first-trimester screening using @entity1465 is not suitable in the case of @entity177 . This article is protected by copyright. All rights reserved.

First-trimester combined screening for trisomy 21 in XXXX with @entity8 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal disease', 'kidney disease'] @entity1465 :: ('93659', 'Gene') :: ['hCGb'] @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic renal disease'] @entity177 :: ('MESH:D051437', 'Disease') :: ['Maternal renal function', 'renal insufficiency', 'maternal renal failure'] @entity1467 :: ('MESH:D004314', 'Disease') :: ['Down syndrome'] @entity15714 :: ('5069', 'Gene') :: ['PAPP-A'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']
@entity1 :: (9606,Species) :: ['women']
